Fibrocell signs license deal with UCLA

Fibrocell Science (FCSC -1.2%) enters an exclusive license agreement with the Regents of the University of California whereby the company acquires the commercial rights to the discoveries and technologies resulting from its ongoing collaboration with UCLA. The partnership enables Fibrocell to expand its Personalized Biologics platform that uses human fibroblasts and stem cells to create patient-specific (autologous) localized therapies.

The licensed patents and technologies pertain to two areas: 1) methods for the use of bone morphogenetic protein 2 (BMP-2) for bone repair and 2) methods for producing pluripotent stem cells (iPSCs) from adult skin cells.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs